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HWEI-FANG CHENG, JUEN-TIAN HSIEH AND CHIA-PO LIN

The live attenuated oral poliovirus vaccine (OPV) has been used for the poliomyelitis eradication program in Taiwan for a long time. Since it is manufactured from a highly thermolabile vaccine strain of poliovirus, it should be stored under the recommended temperature of
-20˚C or below. This study investigated and evaluated the efficiency of the cold chain system
for maintaining the polio vaccine potency in Taiwan. We selected several health stations and
local hospitals/pediatric offices in each County/City of Taiwan to take the OPV samples and
test their potency from Nov. 1997 to Feb. 1998. Our results showed that the type-1 poliovirus
of all OPV samples met the requirements for the potency test, showing titers were higher than
the criteria of the WHO and the ROC (Taiwan) national standard. The type-2 and -3
polioviruses in most of the OPV samples showed titers higher than the criteria, with the exception of a few samples. We found that the degradation of type-2 poliovirus was associated with
the thawed samples, which were stored at temperatures not low enough. The factor that
caused the degradation of the type-3 poliovirus was unclear so far. Nevertheless, the results of
this study indicated that the cold chain system used in Taiwan was generally satisfactory for
the OPV storage.
Key words: cold chain system, oral poliovirus vaccine, potency test.

Since humans are the only host of the
poliovirus, eradication of wild-type poliovirus by
vaccination is feasible(1). The eradication of wild
poliovirus from the Western Hemisphere is a testimony to the effectiveness of the oral poliovirus
vaccine (OPV)(2). Like most parts of the world(3),
OPV (oral Sabin's vaccine) has been used in the

poliomyelitis eradication program in Taiwan for
many years. OPV was first introduced in Taiwan
to prevent children from contracting poliomyelitis
in 1973. Although an outbreak of poliomyelitis
occurred in the Taiwan area in 1982(4), the immunization program reduced the reported incidences
of poliomyelitis by over 70% from 1988 to
1993(1). No wild-strain of poliovirus has been isolated since 1984(1). It was reported that after a 3-
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dose inoculations of OPV, almost all the recipients
become sero-positive against the type-1, -2, and -3
polioviruses(5). Therefore, to accomplish the eradication program successfully, one of the important
parts of the immunization program is to maintain
the efficacy of polio vaccines.
Like other biological products, vaccines have
to be of sufficient stability under the conditions of
transport and storage to maintain their potency at
the point of use(6). The widely used OPV is a nonlyophilized live attenuated vaccine, and is also the
most unstable vaccine in the WHO Expanded
Program of Immunization (EPI)(7,8). Several studies have reported the stability of OPV at ambient
temperatures with regard to various stabilizers
used in it(9,10). OPV is known to retain its potency
over a long period when stored at -20˚C or
below(11). In Taiwan, maintaining OPV at the recommended temperatures of -20˚C or below in a
semi-tropical climate is one of the most important
limiting factors in cold chain system. In this
regard, batch certification of vaccines by national
control authorities and the strict control of temperature and other factors, maintains the potency of
OPV at a satisfactory level. However, the cold
chain system in transportation and storage of vaccines in Taiwan is a three-level transport/storage
system(12). The common childhood vaccines are
usually transported under 2~8˚C conditions from
the level I area to the level II and II areas. In addition, the freezers of health stations, health rooms,
and local hospitals/pediatric offices have different
freezing efficiency for OPV storage. Some OPV
must face an extreme variation in storage temperature and could enter a freezing-thawing cycle
before use. Under these conditions, it can not be
guaranteed that all polio vaccines are able to
maintain effective titers to induce a satisfactory
immune response. Furthermore, OPV is composed
of three-serotype polioviruses, and the potency of
each serotype poliovirus in a trivalent vaccine
should be titrated by using mixtures of the other
two type-specific antisera. However, only the total
virus content (type-1 + type-2 + type-3) was quantified in vaccine samples retrieved from the field
or used to monitor the cold chain(13). Dr. Arya(14)

has also reported that a simultaneous reduction in
the titers of type-2 and type-3 polioviruses would
not be evident during the quantification of the
total viral infectivity.
Yang et al. have demonstrated the type-1
poliovirus potency of OPV samples retrieved
from the three-level storage areas in Taiwan(15).
Their results indicated that the satisfactory percentage of the OPV samples are from 93.4% to
100% during 1992~1994. However, it was still
unknown whether the vaccine potency of the type2 and -3 polioviruses in the OPV had the same
titers as that of the type-1 poliovirus. We have
previously shown the relationship between the
cold chain system and the measles vaccine/
measles-mumps-rubella combined vaccine(12). In
this study, we attempted to find a correlation of
the vaccine potency of OPV and the cold chain
system in Taiwan, and identify the possible factors
affecting vaccine potency. The OPV was randomly sampled from the level II and III areas in our
epidemic prevention system and tested for their
potency. Our results showed that the type-1
poliovirus potency of all OPV samples met its
requirements, and their titers showed no significant difference between the level II and III storage
areas. The OPV samples also maintained their
type-2 and -3 polioviruses potency except for several dissatisfactory cases with lower titers. We
found a correlation between the type-2 poliovirus
degradation and the increase in the thawed vaccine samples during OPV storage. However, the
cause of type-3 poliovirus degradation is still
unknown. It is suggested that it could be due to
the higher level of the minimal storage temperature of the OPV.

I. Materials
Minimum essential medium (MEM) containing Earle’s salts, L-glutamine, and sodium bicarbonate, heat-inactivated and qualified fetal bovine
serum (FBS), antibiotics (100x, lyophilized) and
trypsin/EDTA solution were all purchased from
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Gibco BRL (Grand Island, NY). The neutralizing
antisera of three-serotypes of poliovirus were
kindly provided by SmithKline Beecham
Pharmaceuticals (Belgium). The microtiter plates,
tissue culture flasks, and other plastic accessories
were from Corning/Costar (Nagog Park Action,
MA).

incubated at 35˚C/5% CO2 for 7 to 10 days. At the
end of the incubation period, the numbers of the
specific viral cytopathic effect (CPE) were counted and recorded. The CCID 50 (or TCID 50) per
human dose was calculated using the Reed and
Muench calculation method(16).
V. Statistic Analysis

II. OPV Samples

The SPSS statistic software was used to analyze the experimental results of testing. The student's t test was used for analyzing the results of
the OPV potency tests.

The polio vaccines were sampled from the
health stations and the health rooms/local hospitals/pediatric offices in 23 Counties/Cities in the
Taiwan area. The vaccine samples were coded and
shipped with dry ice, and stored at -20˚C or below
before testing.

During the period from Nov. 1997 to Feb.
1998, we randomly selected the health stations,
health rooms, local hospitals, and pediatric offices
from the level II and the level III storage areas in
Taiwan as the sampling areas. In total, 79 samples
of OPV from the above selected districts were
tested. After the samples were collected, they
were immediately transported to our laboratory
for vaccine potency testing.
Our results showed that the average potency
of the type-1, type-2 and type-3 polioviruses in
the OPV samples were respectively, 6.401
± 0.408, 5.063 ± 0.266 and 5.658 ± 0.358 Log10
TCID50 per single human dose (Table 1). All samples met the criteria of the WHO and the national
standards of the ROC (Taiwan) (not less than 6.0,
5.0 and 5.5 Log10TCID50/dose, respectively). In
addition, the type-1 poliovirus potency of each
OPV sample was higher than the criteria. The
potency of the type-2 and -3 polioviruses in the
OPV samples also met their requirements except
for several dissatisfactory samples. The results of
the type-1 poliovirus are the same as in previous
studies by Yang et al. in 1995(15). Therefore, we

III. Cell and Cell Culture
The Hep2 cells (ATCC CCL-23) purchased
from American Tissue Culture Collection were
established into the master cell bank (MCB) and
working cell bank (WCB) in our laboratory. The
stock Hep2 cultures were prepared from WCB.
They were maintained in MEM supplemented
with 10% FBS in a humidified incubator at 37˚C
under 5% CO 2 condition. The confluent Hep2
cells were subcultured by 0.25% trypsin/EDTA
solution and passed at 15 to 30 generations.
IV. Potency Test
The potency test was conducted according to
the methods for potency testing of vaccine used in
the WHO expanded program on immunization
(13). Serial dilutions of the samples were inoculated in rows of 10 wells of microtiter plates, together with trypsinized Hep2 cell suspension. For the
assay of individual poliovirus serotype in the
trivalent OPV, the highly specific antisera were
used for neutralizing the polioviruses of the other
two serotypes in OPV. The microtiter plates were

Table 1. The average potency of three-serotype polioviruses in the OPV samples
Serotypes
Type-1
Poliovirus Potency (Log10TCID50/dose)
a The

6.401 ±

0.408a

Type-2

Type-3

5.063 ± 0.266

5.658 ± 0.358

average potency of three-serotype polioviruses was shown as mean ± standard deviation.
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believe that most of the OPV in Taiwan has a
good compliance with the cold chain system,
especially the type-1 poliovirus in the OPV, which
maintained satisfactory potency under the storage
and transport conditions. The stabilizer, magnesium chloride (MgCl2), currently used for stabilizing OPV, appears to be able to maintain the type-1
poliovirus potency.
Similar to our previous study for measles vaccine and MMR vaccine(12), we applied the student’s t statistical analysis to compare the potency
of the OPV samples stored in level II and III.
Table 2 shows that the potency of the threeserotype polioviruses in the OPV samples from
the level II areas were slightly higher than the
ones from the level III areas. However, the potency differences were only from 0.024 to 0.068
Log10TCID50 per single human dose, and there
was no significant difference between these two
areas (P > 0.05). This result indicates that
although the level III areas had less satisfactory
storage environments owing to limited funds,
facilities, manpower and other accessories, they
still provided the sufficient ambient temperature
control to maintain the OPV potency during transport and storage.
In this study, we also found that there were
some OPV samples, which had lower titers of the

type-2 and -3 polioviruses. Depending on the storage temperature records from level II/III, and the
frozen or thawed vaccine conditions in sampling,
the average potency of three-serotypes polioviruses in the thawed OPV samples were all lower than
those in the frozen state (Table 3). The potency
differences were from 0.036 to 0.281 Log 10
TCID50 per single human dose, and there was a
significant difference in the type-2 poliovirus
potency between the frozen and thawed vaccines
(P < 0.01). We also found that a dissatisfactory
proportion in the thawed OPV samples was higher
than in the frozen ones, both for type-2 and -3
polioviruses (Table 4). Furthermore, the percentage of the dissatisfactory proportion of the type-2
poliovirus potency in the thawed vaccines reached
46.3%, much higher than the type-3 poliovirus.
Although the WHO recommends 2-8˚C as a storage temperature for OPV(11) and reported that its
potency could be maintained for years at 4˚C with
the MgCl2 stabilizer(17), these requirements mainly focus on the correlation of the cold chain system and the total virus content or type-1 potency(10). That is, our results show that the aqueous
form of the thawed OPV was highly related to
acceleration of the type-2 poliovirus degradation.
The type-2 and type-3 polioviruses are less thermo-stable than the type-1 virus(5). It is possible

Table 2. The poliovirus potency of the OPV sampled from the level II and III storage areas
Storage Area
Level II
Level III

Poliovirus Potency (Log10TCID50/dose)
Type-1

Type-2

Type-3

6.405 ± 0.388a
6.337 ± 0.396

5.040 ± 0.255b
5.024 ± 0.272

5.690 ± 0.379c
5.642 ± 0.351

a,b,c The

statistical analysis was done by student’s T test and there were no significant potency differences
between level II and level III (P > 0.05).

Table 3. The poliovirus potency of the frozen and thawed OPV samples
Poliovirus Potency (Log10TCID50/dose)
Frozen OPV Samples
Thawed OPV Samples
a The

Type-1

Type-2

Type-3

6.401 ± 0.167
6.365 ± 0.162

5.073 ± 0.069a
4.792 ± 0.058

5.703 ± 0.135
5.640 ± 0.141

type-2 poliovirus potency difference between the frozen and the thawed OPV samples was statistically
significant (P < 0.01).
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that the MgCl2 stabilizer used for OPV may be
effective for years to maintain only the type-1
poliovirus potency under thawed vaccine condition. The OPV stability may be improved by use
of other stabilizers such as heavy water (D2O)(18),
the antiviral compound, pirodavir(19), or stricter
thermo-controls in the cold chain system for
maintaining the vaccine potency of the type-2 and
-3 polioviruses.
Pipkin et al. demonstrated that the type-3
component of the live polio vaccine was the most
labile(8). However, in our testing results, the dissatisfactory proportions of the type-2 and trype-3
polioviruses in total OPV samples were 6.3 % and
3.8 %, respectively (data not shown). We showed
that in Taiwan, the more unstable component of
the OPV samples should be the type-2 poliovirus.
We suggest that the major limiting factor for the
type-2 poliovirus potency was the aqueous form
of the thawed OPV due to temperature variation.
Regarding the type-3 poliovirus, we found that
degradation of the type-3 poliovirus seemed to be

Table 4. The percentage of the dissatisfactory
vaccines in the frozen and thawed OPV samples
Percentage of
Dissatisfactory Vaccinesa
Type-2
Type-3
Frozen OPV Samples
Thawed OPV Samples

28.6%
46.3%

14.1%
26.0%

correlated with the storage temperature in each
storage areas. According to the high-low temperature records from the sampling area, the lower the
minimum storage temperature was, the more stable was the type-3 poliovirus (Table 5). Nevertheless, further investigation is needed to clarify this
point. The cooling ability and stability of the
freezer/refrigerator in the vaccine storage areas
are important for vaccine potency of the type-2/-3
polioviruses in the OPV.

In this study, we evaluated the cold chain system for storage of the oral polio vaccines by in
vitro microtitration assay. The results indicated
that the cold chain system in Taiwan provided a
stable environment to maintain the type-1
poliovirus potency. In addition, there was no significant difference in potency of three serotypes
between the OPV samples retrieved from the level
II and III areas. We also found that there several
OPV samples were dissatisfactory in their type-2
and type-3 poliovirus potency. The major contributing factor for accelerating type-2 poliovirus
degradation was the aqueous form of the thawed
OPV due to temperature variation. The cause of
accelerating type-3 poliovirus degradation could
be correlated with the higher level of minimum
storage temperature. However, further investigation is necessary to clarify this point.

a

The dissatisfactory percentage was calculated
from the following formula: the percentage =
numbers of the dissatisfactory samples
x 100
total numbers of the frozen/thawed OPV samples

This study was supported by grants from the

Table 5. The average storage temperature in the type-3 poliovirus potency of the OPV samples
Average Storage Temperature (˚C)
Type-3 Poliovirus Potency
Satisfactory OPV Samples
Dissatisfactory OPV Samples
a

Maximal

Tempa

8.55
9.47

Real Temp
17.06
14.47

Minimal Temp
19.43b
16.21

The maximal, minimal and real temperatures were recorded from the high-low thermometer in the vaccine
storage areas.
b The difference of the average minimal temperature between the satisfactory and dissatisfactory type-3
poliovirus potency of the OPV samples was statistically significant (P < 0.05).
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